Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Associated Therapies: -

Clinical Trials

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2016-05-17

Last Posted Date: 2016-08-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 264

Registration Number: NCT02774278

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Phase 2

Terminated

Conditions: Epidermal Growth Factor Receptor
Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2016-05-12

Last Posted Date: 2019-11-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 43

Registration Number: NCT02770014

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

Phase 3

Conditions: NSCLC

Interventions: Drug: Bevacizumab
Drug: Erlotinib

First Posted Date: 2016-05-03

Last Posted Date: 2018-06-25

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 311

Registration Number: NCT02759614

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Phase 1

Conditions: Pancreatic Neoplasms

Interventions: Drug: CG200745 PPA
Drug: Gemcitabine
Drug: Erlotinib

First Posted Date: 2016-04-13

Last Posted Date: 2019-06-17

Lead Sponsor: CrystalGenomics, Inc.

Target Recruit Count: 24

Registration Number: NCT02737228

Locations: 🇰🇷
Yonsei University Health System, Seoul, Korea, Republic of

Pemetrexed and Erlotinib for Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Pemetrexed
Drug: Erlotinib

First Posted Date: 2016-03-30

Last Posted Date: 2020-01-13

Lead Sponsor: Yonsei University

Target Recruit Count: 50

Registration Number: NCT02723578

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Thoracal Radiotherapy and Tarceva

Phase 2

Terminated

Conditions: Cancer

Interventions: Drug: Erlotinib
Radiation: Radiation

First Posted Date: 2016-03-21

Last Posted Date: 2021-03-30

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 118

Registration Number: NCT02714530

Locations: 🇳🇴
St Olavs Hospital, Trondheim, Norway
🇳🇴
Oslo University Hospital, Oslo, International/Other, Norway

A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Phase 3

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Erlotinib
Drug: Gemcitabine

First Posted Date: 2016-02-29

Last Posted Date: 2017-03-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 80

Registration Number: NCT02694536

Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial

Phase 2

Conditions: Carcinoma, Non-Small-Cell Lung
Brain Neoplasms

Interventions: Drug: Bevacizumab plus erlotinib
Drug: Erlotinib

First Posted Date: 2016-01-14

Last Posted Date: 2018-07-10

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 109

Registration Number: NCT02655536

Locations: 🇨🇳
Department of Oncology, Nationa Taiwan University Hospital, Taipei, Taiwan

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

First Posted Date: 2015-12-23

Last Posted Date: 2020-03-19

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 90

Registration Number: NCT02638428

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Non-squamous Non-small Cell Lung Cancer

Interventions: Drug: Erlotinib
Drug: Bevacizumab

First Posted Date: 2015-12-17

Last Posted Date: 2023-03-24

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 200

Registration Number: NCT02633189

Locations: 🇮🇹
Ospedale Maggiore, Trieste, Italy
🇮🇹
A.O.U. Integrata, Verona, Italy
🇮🇹
A.S.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

and more 52 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy